Clinical Trial Update: Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/LBL [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating a nanobody-based anti-CD5 CAR-T cell therapy for relapsed/refractory precursor T-cell lymphoblastic leukemia/lymphoma (T-ALL/LBL) i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia
• T-cell Lymphoblastic Lymphoma

Drugs mentioned

• Nanobody-Based Anti-CD5 CAR-T (anti-CD5 CAR-T cell therapy)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Phase 1, Phase 2 | Status: RECRUITING